Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

8-Chloroadenosine in Combination with Decitabine and Venetoclax for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with decitabine and venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). 8-Chloroadenosine may help block the formation of growths that may become cancer. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving 8-chloroadenosine in combination with decitabine and venetoclax may help prevent the disease from coming back in patients with relapsed or refractory acute myeloid leukemia.